![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maelor | LSE:MLR | London | Ordinary Share | GB00B2QBY649 | ORD 70P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 100.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1030H Maelor PLC 02 August 2006 Maelor plc AGM Statement 2 August 2006: Maelor plc ("Maelor"; AIM:MLR), the specialist critical care company is today providing the following update on current trading at its Annual General Meeting: "At the time of June's announcement of the Company's results for the financial year ended 31 March 2006, we noted that the year had been one of significant change for the Company. Maelor began its transformation into a business with a clear focus under new leadership. We are pleased to confirm that it continues to make good progress under the guidance and strong leadership of our new Chief Executive Officer, Tim Wright. In the second half of the last financial year the Company rigorously evaluated its existing portfolio and competencies and as a result developed a clear strategy focused on transforming Maelor into a specialist critical care business, while leveraging its non critical care portfolio through efficient partnerships. Trading in the early part of the current financial year has been encouraging and in line with management's expectations. The strategy is being implemented and we are moving forward with a number of projects. Progress includes the active direct promotion of the critical care brand Volplex as well as implementation of the licensing agreement announced in June with Plethora Solutions. This agreement will enable the development of a treatment for interstitial cystitis and painful bladder syndrome, for which the Company has received an upfront payment and will receive milestone and royalty payments. Since the year end the management team has been further strengthened in order to deliver the new strategy. A Commercial Director, experienced in the field of critical care, has been appointed to lead our sales and marketing activities and we are delighted to welcome Nigel Goldsmith to the Board as Finance Director and Company Secretary. With a clear strategy and a management team that has the ability and commitment to deliver, the Board is looking to the future with confidence." Enquiries: Maelor plc, Tim Wright, CEO, Tel: 01978 810153 Financial Dynamics, Billy Clegg/Andrew White, Tel: 020 7831 3113 This information is provided by RNS The company news service from the London Stock Exchange END AGMSSISMESMSEFA
1 Year Maelor Chart |
1 Month Maelor Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions